Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).
Health condition(s) or Problem(s) studied:
Health condition(s) code:
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Neoplasms
Intervention(s):
Control group: Radiotherapy (RT)+ Chemotherapy (CHT)
RT: 50Gy of external RT in 25 sessions of 2Gy each, followed by 85-90Gy of brachytherapy.
CHT: Cisplatin by intravenous route, weekly during RT at doses of 40mg / m2 for 6 doses
Experimental group: Radiotherapy (RT)+ Chemotherapy (CHT) + Paclitaxel
RT: 50Gy of external RT in 25 sessions of 2Gy each, followed by 85-90Gy of brachytherapy.
CHT: Cisplatin by intravenous route, weekly during RT at doses of 40mg / m2 for 6 doses.
Paclitaxel will be recived by intravenous route concomitant with RT and CHT weekly at doses of 40 mg / m2 for 6 doses.
Intervention code:
Paclitaxel
Radiotherapy
Brachytherapy
Cisplatin
Chemoradiotherapy
Drug Therapy
Combined Modality Therapy
Administration, Intravenous